"10.1371_journal.pone.0074325","plos one","2013-09-04T00:00:00Z","Andrew Gassman; Le T Hao; Leena Bhoite; Chad L Bradford; Chi-Bin Chien; Christine E Beattie; John P Manfredi","Sera Prognostics, Inc., Salt Lake City, Utah, United States of America; Department of Neuroscience, The Ohio State University, Columbus, Ohio, United States of America; Technology Commercialization Office, University of Utah, Salt Lake City, Utah, United States of America; Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, Utah, United States of America; Sfida BioLogic, Inc., Salt Lake City, Utah, United States of America","Conceived and designed the experiments: AG CBC CEB JPM. Performed the experiments: AG LTH LB CLB JPM. Analyzed the data: CEB JPM. Contributed reagents/materials/analysis tools: CLB CBC CEB JPM. Wrote the paper: CEB JPM.","The authors have read the journal’s policy and have the following conflicts: JPM is an owner and Chief Scientific Officer of Sfida BioLogic, Inc., which owns patent rights to the compounds that are the subject of this report. Applications for additional patents relevant to these compounds have been filed. Sfida BioLogic has commercial interests in determining the therapeutic potential of the compounds. No other author has competing interests. A patent (vfz., US 7,678,823, “Compounds for Alzheimer’s Disease”) relevant to this report and currently assigned to one of the authors (JPM) has been awarded. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. Affiliations of authors: John Manfredi is founder of and is employed by Sfida Biologic; Andrew Gassman and Chad Bradford are employed by Sera Prognostics; Le T. Hao aud Christine Beattie are employed by the Ohio State University; Leena Bhoite is employed by the University of Utah. These affiliations do not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","09","Andrew Gassman","AG",7,TRUE,4,5,2,2,TRUE,FALSE,FALSE,0,NA,FALSE
